InvestorsObserver
×
News Home

Karyopharm Therapeutics Inc (KPTI) has risen 8.95% in a Week, Should You Buy?

Friday, February 17, 2023 02:50 PM | InvestorsObserver Analysts

Mentioned in this article

Karyopharm Therapeutics Inc (KPTI) has risen 8.95% in a Week, Should You Buy?

Karyopharm Therapeutics Inc (KPTI) is near the middle in its industry group according to InvestorsObserver. KPTI gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Karyopharm Therapeutics Inc gets a 35 rank in the Biotechnology industry. Biotechnology is number 45 out of 148 industries.

Overall Score - 38
KPTI has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on KPTI!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Karyopharm Therapeutics Inc Stock Today?

Karyopharm Therapeutics Inc (KPTI) stock is trading at $3.53 as of 2:48 PM on Friday, Feb 17, a decline of -$0.06, or -1.67% from the previous closing price of $3.59. The stock has traded between $3.39 and $3.62 so far today. Volume today is less active than usual. So far 880,245 shares have traded compared to average volume of 2,893,970 shares. Click Here to get the full Stock Report for Karyopharm Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App